JP2020533381A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533381A5 JP2020533381A5 JP2020515146A JP2020515146A JP2020533381A5 JP 2020533381 A5 JP2020533381 A5 JP 2020533381A5 JP 2020515146 A JP2020515146 A JP 2020515146A JP 2020515146 A JP2020515146 A JP 2020515146A JP 2020533381 A5 JP2020533381 A5 JP 2020533381A5
- Authority
- JP
- Japan
- Prior art keywords
- tradipitant
- patient
- dose
- biomarker
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CAVRKWRKTNINFF-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=CN=CC=2)=C1 CAVRKWRKTNINFF-UHFFFAOYSA-N 0.000 claims description 47
- 229950011232 tradipitant Drugs 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 29
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 12
- 201000008937 atopic dermatitis Diseases 0.000 claims description 12
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 7
- 239000000090 biomarker Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 1
- 101000666657 Homo sapiens Rho-related GTP-binding protein RhoQ Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100038339 Rho-related GTP-binding protein RhoQ Human genes 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 101150116648 rpsP gene Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558303P | 2017-09-13 | 2017-09-13 | |
| US62/558,303 | 2017-09-13 | ||
| US201762572456P | 2017-10-14 | 2017-10-14 | |
| US62/572,456 | 2017-10-14 | ||
| PCT/US2018/048825 WO2019055225A1 (en) | 2017-09-13 | 2018-08-30 | ENHANCED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533381A JP2020533381A (ja) | 2020-11-19 |
| JP2020533381A5 true JP2020533381A5 (enExample) | 2021-09-30 |
| JP7347743B2 JP7347743B2 (ja) | 2023-09-20 |
Family
ID=63684468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515146A Active JP7347743B2 (ja) | 2017-09-13 | 2018-08-30 | トラジピタントによるアトピー性皮膚炎の改善された治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11549147B2 (enExample) |
| EP (2) | EP3681505B1 (enExample) |
| JP (1) | JP7347743B2 (enExample) |
| KR (2) | KR20250036264A (enExample) |
| CN (1) | CN111093671A (enExample) |
| AU (1) | AU2018331267B2 (enExample) |
| CA (1) | CA3073998A1 (enExample) |
| CL (1) | CL2020000655A1 (enExample) |
| IL (1) | IL272949B2 (enExample) |
| MX (2) | MX2020002852A (enExample) |
| WO (1) | WO2019055225A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2770050C2 (ru) * | 2015-03-04 | 2022-04-14 | Ванда Фармасьютиклз Инк. | Способ лечения с применением традипитанта |
| CN112218636B (zh) | 2018-06-08 | 2025-05-06 | 万达制药公司 | 使用川地匹坦进行治疗的方法 |
| KR20220145844A (ko) | 2020-02-25 | 2022-10-31 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
| WO2021195205A1 (en) | 2020-03-26 | 2021-09-30 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| EP3996169B1 (en) | 2020-05-07 | 2025-02-26 | LG Energy Solution, Ltd. | High-nickel electrode sheet and method for manufacturing same |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| AU2023413130A1 (en) | 2022-12-21 | 2025-06-05 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW263498B (enExample) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| AU2003230829B8 (en) | 2002-04-26 | 2008-12-11 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
| SI1501808T1 (sl) | 2002-04-26 | 2008-10-31 | Lilly Co Eli | Antagonisti tahikininskega receptorja |
| JP2004250329A (ja) | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| WO2005042515A1 (en) | 2003-10-24 | 2005-05-12 | Eli Lilly And Company | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| DE102005006217B4 (de) | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| WO2007096782A2 (en) | 2006-02-22 | 2007-08-30 | Valorisation Recherche Hscm, Limited Partnership | Compositions for disorders associated wtth metachromatic cell activation |
| EP2121610B1 (en) | 2006-12-20 | 2014-04-02 | Eli Lilly & Company | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| JP6644328B2 (ja) | 2013-02-28 | 2020-02-12 | ロート製薬株式会社 | アトピー性疾患の発症又は重症化リスクの評価法 |
| US8906951B1 (en) | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| CA2915474A1 (en) | 2013-06-24 | 2014-12-31 | Tigercat Pharma, Inc. | Use of nk-1 receptor antagonist serlopitant in pruritus |
| RU2770050C2 (ru) * | 2015-03-04 | 2022-04-14 | Ванда Фармасьютиклз Инк. | Способ лечения с применением традипитанта |
| IL281569B2 (en) | 2018-09-28 | 2025-04-01 | Vanda Pharmaceuticals Inc | Use of tradipient in motion sickness |
-
2018
- 2018-08-30 CA CA3073998A patent/CA3073998A1/en active Pending
- 2018-08-30 KR KR1020257006413A patent/KR20250036264A/ko active Pending
- 2018-08-30 JP JP2020515146A patent/JP7347743B2/ja active Active
- 2018-08-30 US US16/644,567 patent/US11549147B2/en active Active
- 2018-08-30 WO PCT/US2018/048825 patent/WO2019055225A1/en not_active Ceased
- 2018-08-30 KR KR1020207010029A patent/KR20200054232A/ko not_active Ceased
- 2018-08-30 MX MX2020002852A patent/MX2020002852A/es unknown
- 2018-08-30 IL IL272949A patent/IL272949B2/en unknown
- 2018-08-30 AU AU2018331267A patent/AU2018331267B2/en active Active
- 2018-08-30 EP EP18778635.5A patent/EP3681505B1/en active Active
- 2018-08-30 EP EP24211922.0A patent/EP4487912A3/en active Pending
- 2018-08-30 CN CN201880059276.3A patent/CN111093671A/zh active Pending
-
2020
- 2020-03-12 CL CL2020000655A patent/CL2020000655A1/es unknown
- 2020-03-13 MX MX2024004377A patent/MX2024004377A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Devos et al. | Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease | |
| Niimi | Cough, asthma, and cysteinyl-leukotrienes | |
| Mount | The kidney in hyperuricemia and gout | |
| Kalayci et al. | ALOX5 promoter genotype, asthma severity and LTC4 production by eosinophils | |
| Ruegsegger et al. | Running from disease: molecular mechanisms associating dopamine and leptin signaling in the brain with physical inactivity, obesity, and type 2 diabetes | |
| Weeks et al. | FoxO1 is required for physiological cardiac hypertrophy induced by exercise but not by constitutively active PI3K | |
| JP2017528483A5 (enExample) | ||
| Claes et al. | The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes | |
| Detka et al. | Elevated brain glucose and glycogen concentrations in an animal model of depression | |
| AU2019326405A1 (en) | Methods related to bronchial premalignant lesion severity and progression | |
| JP6528158B2 (ja) | Ｄｒｄ２又はａｎｋｋ１のｓｎｐ遺伝子型に基づく抗精神病治療 | |
| IL272949B2 (en) | Improved treatment of atopic dermatitis with tradipitant | |
| Yan et al. | Influence of component 5a receptor 1 (C5AR1)− 1330T/G polymorphism on nonsedating H1-antihistamines therapy in Chinese patients with chronic spontaneous urticaria | |
| Le Pham et al. | Aspirin-exacerbated respiratory disease: an update | |
| Kim et al. | TBXA2R gene polymorphism and responsiveness to leukotriene receptor antagonist in children with asthma | |
| Kang et al. | Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia | |
| Aoki et al. | Factors that affect intravenous patient-controlled analgesia for postoperative pain following orthognathic surgery for mandibular prognathism | |
| Kurose et al. | Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression | |
| JP2023521754A5 (enExample) | ||
| US20210393591A1 (en) | Treatments for charcot-marie-tooth disease | |
| Israel | Genetics and the variability of treatment response in asthma | |
| Taşkın et al. | The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population | |
| Kaplan et al. | α1-Antitrypsin deficiency: Forgotten etiology | |
| US9603857B2 (en) | Inflammatory disease model and method of treatment | |
| Ulrik et al. | Add‐on montelukast to inhaled corticosteroids protects against excessive airway narrowing |